Eyeing big growth in Indonesia, Germany-based drugmaker Fresenius Kabi has agreed to buy a 51% share in the country's PT Ethica Industri Farmasi. Sources tell The Wall Street Journal that the deal could be worth $200 million. It's just the latest deal in the Asian market, which is expected to grow much faster than Europe and the U.S. Report